본문 바로가기 주메뉴 바로가기

NEWS


[October 25, 2021] Noile-Immune Biotech Enters Collaboration with DAIICHI SANKYO COMPANY, LIMITED on Technology Assessment

Attechment(0)첨부파일 보기

Research Agreement to assess Noile’s PRIME technology was made between and by Noile and Daiichi Sankyo.

We are pleased to post the news that Daiichi Sankyo Co.,Ltd., has made a research agreement to assess PRIME technology with Noile-Immune (herein, Noile), one of our portfolio companies. Until now, Noile has made a series of wonderful collaborations with top tier global biotechs and pharmaceutical companies including top three major Japanese pharmaceutical companies: Takeda, Chugai, and Daiichi Sankyo, and is now conducting human clinical studies targeting solid cancer either for itself (NIB101) or with the help of partner company (NIB102). The number of pipeline entering into human clinical stage is expected to increase gradually.


https://www.noile-immune.com/dcms_media/other/20211025_News_DS-Noile_PR_en.pdf 



Noile-Immune Biotech Enters Collaboration with DAIICHI SANKYO COMPANY, LIMITED on Technology Assessment 


Tokyo, Japan (October 25, 2021) - Noile-Immune Biotech Inc. (“Noile-Immune”) today announced that Noile-Immune and DAIICHI SANKYO COMPANY, LIMITED (“Daiichi Sankyo”) have entered into the agreement regarding PRIME (Proliferation inducing and migration enhancing) technology assessment. 

PRIME technology has a capability of not only enhancing the functions of gene-modified immune cells such as CAR-T cells, but also improving the ability of patient's own immune systems to treat cancer1). Noile-Immune has the exclusive right to implement PRIME technology. 

Under this agreement, Daiichi Sankyo will evaluate Noile-Immune’s PRIME technology with collaborative works with Noile-Immune, and Daiichi Sankyo will pay Noile-Immune the technology access fee. Further details of this agreement are not disclosed. 

1) Adachi K et al. Nat Biotechnol, 2018;36(4):346-351. 



 

List